Who Paid My Doc
Jason Patterson
Foot and Ankle Surgery Gilbert, AZ Medical Doctor
NPI 1831326909 CMS profile 355293
1675 E Melrose St Ste 101-103, Gilbert, AZ 85297
General payments
$132,007
Research payments
$9,715
Ownership & investment interest
$0
Research they led as principal investigator
$12,868
Through program year 2025, Jason Patterson of Gilbert, AZ is reported in the CMS Open Payments database as having received $132,007 across 312 general payments and $9,715 in research payments paid to them. Separately, studies naming them as principal investigator received $12,868 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 88th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $51,244 | 73 | |
| 2025 | Research | $1,960 | 2 | |
| 2024 | General | $20,663 | 84 | |
| 2024 | Research | $5,178 | 3 | |
| 2023 | General | $49,320 | 49 | |
| 2023 | Research | $2,577 | 2 | |
| 2022 | General | $3,212 | 19 | |
| 2021 | General | $1,609 | 43 | |
| 2020 | General | $307 | 20 | |
| 2019 | General | $5,652 | 24 |
Beside peers
- Jason Patterson
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Jason Patterson were reported at $51,244. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Jason Patterson | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,652 | $1,327 | $279–$5,421 | $163 |
| 2020 | $307 | $795 | $121–$3,473 | $114 |
| 2021 | $1,609 | $1,289 | $201–$4,963 | $132 |
| 2022 | $3,212 | $1,539 | $270–$6,067 | $149 |
| 2023 | $49,320 | $1,117 | $257–$5,264 | $160 |
| 2024 | $20,663 | $1,064 | $235–$4,944 | $164 |
| 2025 | $51,244 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
92
Drug cost
$576
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 31 | $210 | |
| Methylprednisolone | Generic | 22 | $172 | |
| Oxycodone Hcl | Generic | 27 | $113 | |
| Cephalexin | Generic | 12 | $81 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 110 billing codesPaid by Medicare
$123,445
Medicare patients
344
Services billed
3,313
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Arthritis | 68% | |
| Ischemic heart disease | 25% | |
| Depression | 22% | |
| Diabetes | 19% | |
| Chronic kidney disease | 19% | |
| Osteoporosis | 19% | |
| Cancer | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 12 | 52 | $287 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 32 | 1,880 | $184 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 16 | 23 | $99 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
319 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Arizona
Geoffrey Landis
Foot and Ankle Surgery · Tucson, AZ
David Jaffe
Foot and Ankle Surgery · Phoenix, AZ
Christopher Diefenbach
Foot and Ankle Surgery · Flagstaff, AZ
Jason Lake
Foot and Ankle Surgery · Gilbert, AZ
Braden Boyer
Foot and Ankle Surgery · Phoenix, AZ
Martin Weisman
Foot and Ankle Surgery · Phoenix, AZ
Related records
Foot and Ankle Surgery in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.